The Next Frontier: Novel Ways to Engage Innate and Adaptive Immunity to Fight Cancer

3:00 PM - 3:45 PM (EDT), Wednesday, June 16, 2021
Search General Info
Search Education
Search Partnering Companies

Effective targeting and activation of innate and adaptive immune cells represents a highly promising frontier in cancer therapy. Two distinct approaches are getting particular attention; the first aims to specifically recruit the patient’s own effector cells for tumor cell killing using bispecific binding molecules, and the second aims to genetically enhance effector cells ex vivo for developing treatments.  Hear from leading innovators about developments at the crossroads of these novel strategies.

Speakers
photo
Prof
UCL
photo
Chief Executive Officer
Immunocore PLC
photo
Chief Medical Officer and Executive Vice President of Research & Development
GammaDelta Therapeutics
photo
EVP and Head of R&D
LAVA Therapeutics BV
photo
Chief Scientific Officer
Nkarta Therapeutics, Inc.